

PredicineBEACON™

Introducing the Next-Generation Actionable MRD Assay

An ultra-sensitive Minimal Residual Disease (MRD) detection that is not limited by baseline tissue sample availability

50


Mutation personalized panel

500

Actionable mutations tracked

0.005%


Limit of detection (LOD)



Methods and Reporting

- Flexibility in baseline profiling - tissue or liquid biopsy (including blood, plasma, and urine)
- Ultra-sensitive in MRD detection - 0.005% LOD
- Includes genome-wide copy number changes
- Longitudinally tracks up to 50 personalized mutations
- Includes analysis of 500 actionable approved therapy selection mutations

Workflow



PredicineBEACON addresses the challenges faced by conventional MRD assays

- Tissue-baseline agnostic solution: Baseline analysis can be obtained via blood, urine, or tissue
- Ultra-sensitive: Ability to identify alterations missed by less sensitive assays
- Multi-dimensional: Detects all types of DNA changes, including fusions and copy number changes
- Actionable MRD result: Upon recurrence, actionable mutation analysis will provide treatment insights into potentially targetable alterations

Product details



Baseline Profiling
Blood, Urine, or Tissue



Multi-Dimensional MRD Detection
Mutations, Fusions, and Copy Number Changes





Ultra Sensitivity
0.005% Limit of Detection



Actionable MRD
500 actionable mutations

Case 1: Tissue-free, urine baseline-informed MRD in neoadjuvant MIBC

Longitudinal personalized urinary tumor DNA analysis in muscle invasive bladder cancer cancer from neoadjuvant immunotherapy trial RJBLC-12N003



	RZ20	RZ18	RZ15	RZ08	RZ13	RZ06	RZ10	RZ09	RZ01	RZ14	RZ16	RZ07	RZ17	RZ03	RZ11	RZ05	RZ19	RZ02	RZ12	RZ04
RECIST1.1	CR	CR	CR	PR	PR	PR	PR	PR	PR	PR	PR	PR	PR	PR	SD	SD	SD	SD	PD	SD
Pathology	CR	CR	CR	CR	CR	CR	CR	CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR	non-CR
MRD	-	NA	-	+	+	NA	-	+	+	+	+	+	+	+	+	+	+	+	+	+